177 related articles for article (PubMed ID: 26715008)
1. Dual-drug RGD conjugates provide enhanced cytotoxicity to melanoma and non-small lung cancer cells.
Gilad Y; Noy E; Senderowitz H; Albeck A; Firer MA; Gellerman G
Biopolymers; 2016 Mar; 106(2):160-171. PubMed ID: 26715008
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery.
Gilad Y; Noy E; Senderowitz H; Albeck A; Firer MA; Gellerman G
Bioorg Med Chem; 2016 Jan; 24(2):294-303. PubMed ID: 26719208
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety.
Redko B; Ragozin E; Andreii B; Helena T; Amnon A; Talia SZ; Mor OH; Genady K; Gary G
Biopolymers; 2015 Nov; 104(6):743-52. PubMed ID: 26058565
[TBL] [Abstract][Full Text] [Related]
4. Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma.
Redko B; Tuchinsky H; Segal T; Tobi D; Luboshits G; Ashur-Fabian O; Pinhasov A; Gerlitz G; Gellerman G
Oncotarget; 2017 Jan; 8(1):757-768. PubMed ID: 27768593
[TBL] [Abstract][Full Text] [Related]
5. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of (68)Ga-labeled NOTA-RGD-GE11 heterodimeric peptide for dual integrin and epidermal growth factor receptor-targeted tumor imaging.
Yu HM; Chen JH; Lin KL; Lin WJ
J Labelled Comp Radiopharm; 2015 Jun; 58(7):299-303. PubMed ID: 25997858
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
9. Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.
Tripodi AAP; Tóth S; Enyedi KN; Schlosser G; Szakács G; Mező G
Beilstein J Org Chem; 2018; 14():911-918. PubMed ID: 29765472
[TBL] [Abstract][Full Text] [Related]
10. RGD Peptidomimetic MMAE-Conjugate Addressing Integrin αVβ3-Expressing Cells with High Targeting Index.
Paulus J; Nachtigall B; Meyer P; Sewald N
Chemistry; 2023 Feb; 29(12):e202203476. PubMed ID: 36454662
[TBL] [Abstract][Full Text] [Related]
11. RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping.
Ke T; Jeong EK; Wang X; Feng Y; Parker DL; Lu ZR
Int J Nanomedicine; 2007; 2(2):191-9. PubMed ID: 17722547
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.
Ryppa C; Mann-Steinberg H; Biniossek ML; Satchi-Fainaro R; Kratz F
Int J Pharm; 2009 Feb; 368(1-2):89-97. PubMed ID: 18992308
[TBL] [Abstract][Full Text] [Related]
13. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers.
Garanger E; Boturyn D; Dumy P
Anticancer Agents Med Chem; 2007 Sep; 7(5):552-8. PubMed ID: 17896915
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent.
Zhang X; Chen X
Appl Radiat Isot; 2007 Jan; 65(1):70-8. PubMed ID: 17011200
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance to chlorambucil in murine B-cell leukemic cells is overcome by its conjugation to a targeting peptide.
Gellerman G; Baskin S; Galia L; Gilad Y; Firer MA
Anticancer Drugs; 2013 Feb; 24(2):112-9. PubMed ID: 23187462
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Biological Characterization of Monomeric and Tetrameric RGD-Cryptophycin Conjugates.
Borbély A; Thoreau F; Figueras E; Kadri M; Coll JL; Boturyn D; Sewald N
Chemistry; 2020 Feb; 26(12):2602-2605. PubMed ID: 31943410
[TBL] [Abstract][Full Text] [Related]
17. Enzyme-triggered delivery of chlorambucil from conjugates based on the cell-penetrating peptide BP16.
Soler M; González-Bártulos M; Figueras E; Ribas X; Costas M; Massaguer A; Planas M; Feliu L
Org Biomol Chem; 2015 Feb; 13(5):1470-80. PubMed ID: 25474438
[TBL] [Abstract][Full Text] [Related]
18. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, DNA binding, and sequence specificity of DNA alkylation by some novel cyclic peptide-chlorambucil conjugates.
Sheh L; Chang HW; Ong CW; Chen SL; Bailly C; Linssen RC; Waring MJ
Anticancer Drug Des; 1995 Jul; 10(5):373-88. PubMed ID: 7639928
[TBL] [Abstract][Full Text] [Related]
20. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
